热门资讯> 正文

Lucid Diagnostics非GAAP每股收益为-0.10美元

2025-08-13 20:28

Lucid Diagnostics press release (NASDAQ:LUCD): Q2 Non-GAAP EPS of -$0.10.
Processed 2,756 EsoGuard tests and recognized revenue of $1.2 million, ending quarter with over $30 million in pro forma cash and extending runway well past upcoming reimbursement milestones.

More on Lucid Diagnostics

Lucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIG
Lucid says meeting scheduled to determine Medicare coverage for cancer test
Seeking Alpha’s Quant Rating on Lucid Diagnostics
Historical earnings data for Lucid Diagnostics
Financial information for Lucid Diagnostics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。